Key result
Pre-PCI Impella fails to reduce acute kidney injury or renal replacement therapy in AMI-CS.
Why the study?
Although initiating Impella support prior to PCI in AMI-CS is associated with lower mortality and comparable safety compared with later initiation, its effect on renal events remained unclear.
Does pre-PCI Impella support reduce acute kidney injury or renal replacement therapy compared to initiation during/after PCI in patients with acute myocardial infarction and cardiogenic shock?
Meta-Analysis
Does pre-PCI Impella support reduce acute kidney injury or renal replacement therapy compared to initiation during/after PCI in patients with acute myocardial infarction and cardiogenic shock?
Pre-PCI Impella initiation in AMI-CS is associated with lower short-term mortality (RR 0.70) without a statistically significant reduction in overall pooled adverse renal events, though sensitivity analysis suggests potential renal benefit.
Answers are grounded in this paper and cite their sources.
Pre-PCI Impella was not associated with reduced renal events in AMI-CS; leaves open timing effects on kidney injury pending randomized trials.
Background Recent studies suggest that initiation of Impella support, prior to percutaneous coronary intervention (PCI), in acute myocardial infarction with cardiogenic shock (AMI-CS) is associated with lower short-term and mid-term mortality while maintaining comparable safety outcomes to later initiation. However, its effect on renal events remains unclear. This study aims to synthesize available evidence on this outcome. Methods We systematically searched MEDLINE and EMBASE from inception to September 2025 to compare Impella support before PCI versus during/after PCI in AMI-CS. The primary outcome was acute kidney injury or renal replacement therapy (RRT); secondary outcomes included mortality and safety events, such as stroke. Relative risks (RRs) with 95% confidence intervals (CIs) were pooled using the generic inverse variance method. Results Ten observational studies were included, with four reporting renal outcomes. Pre-PCI Impella initiation was not significantly associated with fewer adverse renal events (RR, 0.75; 95% CI, 0.45–1.24; P = 0.17). Sensitivity analysis excluding Hemradj et al. demonstrated a significant association with lower renal risk (RR, 0.64; 95% CI, 0.42–0.96; P = 0.0412). Pre-PCI initiation was associated with lower short-term mortality (RR, 0.70; 95% CI, 0.60–0.81), while stroke incidence did not differ significantly (RR, 0.72; 95% CI, 0.15–3.32). Conclusion Pre-PCI Impella support in AMI-CS was not significantly associated with differences in renal outcomes, although these results are sensitive to the exclusion of specific studies. Larger studies are needed to confirm these findings, and account for underlying confounding variables, to clarify the underlying mechanism.
No takes yet. Share an insight, caveat, or question.
Sass et al. (2026) conducted a meta-analysis in Acute myocardial infarction with cardiogenic shock (AMI-CS). Pre-PCI Impella mechanical circulatory support initiation vs. Impella initiation during or after PCI was evaluated on Acute kidney injury or renal replacement therapy (RRT) (RR 0.75, 95% CI 0.45-1.24, p=0.17). Pre-PCI Impella support in AMI-CS was not associated with lower acute kidney injury or renal replacement therapy compared to initiation during/after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: